Discreet but a force to be reckoned with in the biopharmaceutical world, Dr Herriot Tabuteau enters this year’s Forbes 2025 ranking with an estimated fortune of $1.1 billion. This Haitian-born physician heads Axsome Therapeutics, a company he founded in 2012 to revolutionize the treatment of central nervous system disorders.
Going against the grain of pharmaceutical giants who were turning away from neuroscience, Tabuteau bet on research into mental health: depression, Alzheimer’s, narcolepsy, ADHD… Thanks to major clinical advances, several treatments developed by Axsome have received “breakthrough therapy” designation from the FDA, marking a turning point in the field.
Since going public in 2015 (NASDAQ: AXSM), the company has gone from strength to strength. With around 15% of the shares, Tabuteau is now reaping the rewards, without ever abandoning his primary mission: to make a tangible difference to patients’ lives.
With an MD from Yale and a degree in molecular biology from Wesleyan University, he also cut his teeth in finance at Goldman Sachs and SAC Capital. This dual scientific and financial profile has shaped his unique approach to biomedical innovation.
Born in Haiti and raised in Manhattan in a stimulating scientific environment, Herriot Tabuteau remains deeply marked by his origins and his New York Catholic upbringing. He pays tribute to his parents: a hard-working Haitian father, and an African-American mother involved in the civil rights struggle, who passed on to him a passion for art and culture.
Now a billionaire, he continues to lead Axsome with the same determination, proving that medical innovation can also change the world.
Soutenez Hebdo24 : pour une information libre et fiable.
Faire un don
